TWI748541B - eIF4E抑制性化合物與方法 - Google Patents

eIF4E抑制性化合物與方法 Download PDF

Info

Publication number
TWI748541B
TWI748541B TW109122116A TW109122116A TWI748541B TW I748541 B TWI748541 B TW I748541B TW 109122116 A TW109122116 A TW 109122116A TW 109122116 A TW109122116 A TW 109122116A TW I748541 B TWI748541 B TW I748541B
Authority
TW
Taiwan
Prior art keywords
cancer
mmol
alkyl
compound
reaction mixture
Prior art date
Application number
TW109122116A
Other languages
English (en)
Chinese (zh)
Other versions
TW202115058A (zh
Inventor
山繆爾 史派瑞
新 向
賈斯汀 恩斯特
席格菲 瑞奇
保羅 史倫格勒
麥克 夏赫菲
帝歐 米榭爾斯
克利斯汀 奈爾維斯基
金 崔倫
格瑞克 派卡德
艾倫 格普斯
卡維里 烏卡蘭
向山貴祐
Original Assignee
美商eFFECTOR醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商eFFECTOR醫療公司 filed Critical 美商eFFECTOR醫療公司
Publication of TW202115058A publication Critical patent/TW202115058A/zh
Application granted granted Critical
Publication of TWI748541B publication Critical patent/TWI748541B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW109122116A 2019-07-02 2020-06-30 eIF4E抑制性化合物與方法 TWI748541B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962869662P 2019-07-02 2019-07-02
US62/869,662 2019-07-02

Publications (2)

Publication Number Publication Date
TW202115058A TW202115058A (zh) 2021-04-16
TWI748541B true TWI748541B (zh) 2021-12-01

Family

ID=71614984

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109122116A TWI748541B (zh) 2019-07-02 2020-06-30 eIF4E抑制性化合物與方法

Country Status (15)

Country Link
US (2) US11286268B1 (cg-RX-API-DMAC10.html)
EP (1) EP3994139A1 (cg-RX-API-DMAC10.html)
JP (1) JP7595055B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220061945A (cg-RX-API-DMAC10.html)
CN (1) CN114269756B (cg-RX-API-DMAC10.html)
AR (1) AR119339A1 (cg-RX-API-DMAC10.html)
AU (1) AU2020299362B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021026682A2 (cg-RX-API-DMAC10.html)
CA (2) CA3188446A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021003573A1 (cg-RX-API-DMAC10.html)
IL (1) IL289456A (cg-RX-API-DMAC10.html)
PY (1) PY2031844A (cg-RX-API-DMAC10.html)
TW (1) TWI748541B (cg-RX-API-DMAC10.html)
UY (1) UY38773A (cg-RX-API-DMAC10.html)
WO (1) WO2021003157A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220378821A1 (en) * 2019-07-02 2022-12-01 Effector Therapeutics, Inc. Methods of treating braf-mutated cancer cells
EP4076438A4 (en) * 2019-12-18 2023-11-29 Merck Sharp & Dohme LLC BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HERPES VIRUSES
WO2021240337A1 (en) * 2020-05-27 2021-12-02 Effector Therapeutics, Inc. Covalent modifiers of eif4e inhibiting compounds
KR20230124648A (ko) * 2020-12-22 2023-08-25 화이자 인코포레이티드 Eif4e 억제제의 고체 형태
EP4430029A4 (en) * 2021-11-09 2025-09-10 Vigil Neuroscience Inc HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL AGONISTS 2 AND METHODS OF USE
AU2023375677A1 (en) * 2022-11-10 2025-06-05 Ribometrix, Inc. COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF
TW202428278A (zh) * 2022-12-23 2024-07-16 大陸商南京聖和藥業股份有限公司 作為eIF4E抑制劑的化合物及其應用
IL326137A (en) 2023-07-28 2026-03-01 Cogent Biosciences Inc PI3K inhibitors
WO2025101516A1 (en) * 2023-11-06 2025-05-15 Ribometrix, Inc. Methods of using eif4e inhibitors for treating cancer
WO2025120599A1 (en) * 2023-12-08 2025-06-12 Ribometrix, Inc. METHODS OF USING eIF4E INHIBITORS FOR TREATING CANCER

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014179237A1 (en) * 2013-04-29 2014-11-06 Vanderbilt University Substituted 3-benzylquinoxalin-4(3h)-one analogs as positive allosteric modulators of muscarinic acetycholine receptor m1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255161A1 (en) 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
CA2724426A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
JP2017510552A (ja) 2014-02-07 2017-04-13 イーフェクター セラピューティクス, インコーポレイテッド 線維性疾患を治療するための方法
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 MnK抑制劑及其相關方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014179237A1 (en) * 2013-04-29 2014-11-06 Vanderbilt University Substituted 3-benzylquinoxalin-4(3h)-one analogs as positive allosteric modulators of muscarinic acetycholine receptor m1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Giri RS, et al. "Synthesis and evaluation of quinazolinone derivatives as inhibitors of NF-kappaB, AP-1 mediated transcription and eIF-4E mediated translational activation: inhibitors of multi-phathways involve in cancer" European Journal of Medicinal Chemistry 2010;45(9):3558-3563 *

Also Published As

Publication number Publication date
CA3188446A1 (en) 2021-01-07
JP7595055B2 (ja) 2024-12-05
US20230108594A1 (en) 2023-04-06
PY2031844A (es) 2021-04-19
CN114269756A (zh) 2022-04-01
CA3085255A1 (en) 2021-01-02
TW202115058A (zh) 2021-04-16
AR119339A1 (es) 2021-12-09
KR20220061945A (ko) 2022-05-13
WO2021003157A1 (en) 2021-01-07
UY38773A (es) 2021-01-29
AU2020299362A1 (en) 2022-02-24
IL289456A (en) 2022-02-01
US11286268B1 (en) 2022-03-29
AU2020299362B2 (en) 2026-02-26
CL2021003573A1 (es) 2022-08-12
BR112021026682A2 (pt) 2022-03-15
EP3994139A1 (en) 2022-05-11
JP2022539256A (ja) 2022-09-07
CN114269756B (zh) 2024-05-14

Similar Documents

Publication Publication Date Title
CN114269756B (zh) 抑制eif4e的4-氧代-3,4-二氢吡啶并[3,4-d]嘧啶化合物
JP6903796B2 (ja) Fgfr4阻害剤としての二環式複素環
JP6647434B2 (ja) 特定のトリアゾロピリジンおよびトリアゾロピラジン、それらの組成物並びにそれらの使用方法
JP6892444B2 (ja) Mnk1およびmnk2のイソインドリン、アザイソインドリン、ジヒドロインデノンならびにジヒドロアザインデノン阻害薬
JP6615797B2 (ja) Mnk阻害薬およびそれに関連する方法
KR101871436B1 (ko) 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물
US11014926B2 (en) Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2
TW202000666A (zh) 作為a2a/a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
JP2015508785A (ja) ピリジニル及びピリミジニルスルホキシド及びスルホン誘導体
TW200900404A (en) Pyrazolopyrimidine analogs and their use as mTOR kinase and PI3 kinase inhibitors
TW202135824A (zh) 包含a2a/a2b及pd-1/pd-l1抑制劑之組合療法
JP2023508978A (ja) エクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ1(enpp1)モジュレーター及びその使用
CN110312717B (zh) 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用